Onartuzumab
- Generic Name
- Onartuzumab
- Drug Type
- Biotech
- CAS Number
- 1133766-06-9
- Unique Ingredient Identifier
- MS1J9720WC
- Background
Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02488330
- Locations
- 🇫🇷
Hopital Roger Salengro, Lille, France
🇯🇵National Hospital Organization Shikoku Cancer Center, Ehime, Japan
🇮🇹Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Torino, Piemonte, Italy
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02044601
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 530
- Registration Number
- NCT02031744
- Locations
- 🇨🇳
Southwest Hospital , Third Military Medical University, Chongqing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳Jilin Cancer Hospital, Changchun, China
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01974258
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01897038
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT01887886
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 564
- Registration Number
- NCT01662869
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT01632228
- Locations
- 🇩🇪
Ärztehaus Velen, Ibbenbühren, Germany
🇨🇦McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT01590719
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01519804
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.